A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS

The KRAS gene is frequently mutated in multiple cancer types, but it fell off the drug discovery radar for many years because of its inherent “undruggable” structure and undefined biological properties. As reported in the paper entitled “Suppression of KRas-mutant cancer through the combined inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales: Pang, Xiufeng, Liu, Mingyao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Highlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5086049/
https://www.ncbi.nlm.nih.gov/pubmed/27793187
http://dx.doi.org/10.1186/s40880-016-0154-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5086049/
https://www.ncbi.nlm.nih.gov/pubmed/27793187
http://dx.doi.org/10.1186/s40880-016-0154-7

Ejemplares similares